In a 12-week study, participants receiving 1 mg daily lost an average of 2.6 kg (approximately 5.7 pounds) compared to 0.8 kg in the placebo group
But the biggest immediate risk, he says, is premature commercialization, as clinics could misinterpret the advisory vote and start marketing the peptides before the FDA makes its decisionwhich could end in warning letters, frozen accounts, and severe disciplinary action from state pharmacy boards
Seleem AK, El Refaeey AA, Shaalan D, Sherbiny Y, Badawy A
10.1038/nature09325 23 HuZ.ZhangH.YiB.YangS.LiuJ.HuJ.et al (2020)
doi:10.1371/journal.pone.0178868 Jones ML, Martoni CJ, Prakash S